这是一篇来自已证抗体库的有关
人类 maspin的综述,是根据6篇发表使用所有方法的文章归纳的。这综述旨在帮助来邦网的访客找到最适合maspin 抗体。
maspin 同义词: PI5; maspin; serpin B5; PI-5; peptidase inhibitor 5; protease inhibitor 5 (maspin); serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 5; serpin peptidase inhibitor, clade B (ovalbumin), member 5
赛信通(上海)生物试剂有限公司
兔 多克隆 | | 赛信通(上海)生物试剂有限公司 maspin抗体(Cell Signaling Technology, 9117)被用于被用于免疫印迹在人类样本上浓度为1:1000 (图 5a). PLoS ONE (2014) ncbi |
碧迪BD
小鼠 单克隆(G167-70) | - 免疫细胞化学; 人类; 图 2b
- 免疫印迹; 人类; 图 1b
| 碧迪BD maspin抗体(BD Pharmingen, 554292)被用于被用于免疫细胞化学在人类样本上 (图 2b) 和 被用于免疫印迹在人类样本上 (图 1b). Oncotarget (2017) ncbi |
小鼠 单克隆(G167-70) | | 碧迪BD maspin抗体(BD Biosciences, 554292)被用于被用于免疫印迹在人类样本上 (图 2). Int J Mol Sci (2016) ncbi |
小鼠 单克隆(G167-70) | | 碧迪BD maspin抗体(BD Biosciences, 554292)被用于被用于免疫印迹在人类样本上 (图 3). Cancer Lett (2016) ncbi |
小鼠 单克隆(G167-70) | | 碧迪BD maspin抗体(BD Biosciences, 554292)被用于被用于免疫印迹在人类样本上 (图 6c). Sci Rep (2015) ncbi |
小鼠 单克隆(G167-70) | | 碧迪BD maspin抗体(BD Pharmingen, clone G167-70)被用于被用于免疫组化-石蜡切片在人类样本上浓度为1:200. BMC Cancer (2015) ncbi |
Dean I, Dzinic S, Bernardo M, Zou Y, Kimler V, Li X,
et al. The secretion and biological function of tumor suppressor maspin as an exosome cargo protein. Oncotarget. 2017;8:8043-8056
pubmed 出版商
Lee J, Chiang K, Feng T, Chen Y, Chuang S, Tsui K,
et al. The Iron Chelator, Dp44mT, Effectively Inhibits Human Oral Squamous Cell Carcinoma Cell Growth in Vitro and in Vivo. Int J Mol Sci. 2016;17:
pubmed 出版商
Tsui K, Lin Y, Chung L, Chuang S, Feng T, Chiang K,
et al. Prostate-derived ets factor represses tumorigenesis and modulates epithelial-to-mesenchymal transition in bladder carcinoma cells. Cancer Lett. 2016;375:142-151
pubmed 出版商
Tsui K, Hsu S, Chung L, Lin Y, Feng T, Lee T,
et al. Growth differentiation factor-15: a p53- and demethylation-upregulating gene represses cell proliferation, invasion, and tumorigenesis in bladder carcinoma cells. Sci Rep. 2015;5:12870
pubmed 出版商
Robl B, Pauli C, Botter S, Bode Lesniewska B, Fuchs B. Prognostic value of tumor suppressors in osteosarcoma before and after neoadjuvant chemotherapy. BMC Cancer. 2015;15:379
pubmed 出版商
O Hainmhire E, Quartuccio S, Cheng W, Ahmed R, King S, Burdette J. Mutation or loss of p53 differentially modifies TGF? action in ovarian cancer. PLoS ONE. 2014;9:e89553
pubmed 出版商